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Aim To compare dosimetry, efficacy, and toxicity of inten-
sity-modulated radiation therapy (IMRT) with para-aortic 
field radiotherapy in patients with para-aortic lymph node 
(PALN) metastasis of cervical cancer.
Methods This prospective study examined 60 patients 
with cervical cancer with PALN metastasis who underwent 
whole-pelvis radiotherapy followed by brachytherapy be-
tween November 1, 2004 and May 31, 2008. After 3 cycles 
of chemotherapy, patients were serially allocated into two 
groups and treated with IMRT or para-aortic field RT at 
doses of 58-68 Gy and 45-50 Gy, respectively. Treatment 
response was evaluated and toxicities were assessed. Pa-
tients in the IMRT group were treated with both para-aortic 
field RT and IMRT in order to compare the exposure dose 
of organs at risk.
Results In the IMRT group, the mean dose delivered to the 
planning target volume was 67.5 Gy. At least 99% of the 
gross tumor volume received effective coverage and radi-
cal dose (median, 63.5 Gy; range, 54.5-66) during treatment. 
IMRT plans yielded better dose conformity to the target 
and better sparing of the spinal cord and small intestine 
than para-aortic field RT. The IMRT patients experienced 
less acute and chronic toxicities. The IMRT group also had 
higher 2- and 3-year survival rates than the para-aortic RT 
group (2-year, 58.8% vs 25.0%, P = 0.019; 3-year, 36.4% vs 
15.6%, P = 0.016). However, no significant difference was 
found in 1-year survival (67.7% vs 51.3%, P =0.201). The me-
dian survival in the IMRT group was 25 months (range, 3 to 
37 months). The actuarial overall survival, disease-free sur-
vival, and locoregional control rates at 2 years were 67%, 
77%, and 88%, respectively, in the IMRT group.
Conclusions IMRT provides better clinical outcomes than 
para-aortic field radiotherapy in patients with PALN metas-
tasis. However, cervical local and distal recurrence remain a 
problem. Long-term follow-up and studies involving more 
patients are needed to confirm our results.
Xue-lian Du, Xiu-gui 
Sheng, Tao Jiang, Hao Yu, 
Yu-feng Yan, Rong Gao, 
Chun-hua Lu, Qing-shui Li
Department of Gynecologic 
Oncology, Shandong Tumor 
Hospital and Institute, Jinan, 
People’s Republic of China
Received: February 14, 2010
Accepted: June 7, 2010
Correspondence to:  
Xiu-gui Sheng 
Department of Gynecologic 
Oncology 
Shandong Tumor Hospital and 
Institute 




Therapy Versus Para-aortic 
Field Radiotherapy to Treat 
Para-aortic Lymph Node 
Metastasis in Cervical Cancer: 
Prospective Study
CLINICAL SCIENCES  
 
doi: 10.3325/cmj.2010.51.229
CLINICAL SCIENCES230 Croat Med J. 2010; 51: 229-36
www.cmj.hr
Cervical cancer can metastasize to para-aortic lymph nodes 
(PALN), which are not covered in the conventional expo-
sure field (1,2). According to Fletcher (3), some patients 
with positive PALNs show better long-term survival when 
treated with radiation therapy (RT) of the abdominal para-
aortic lymph nodes in a procedure known as para-aortic 
field RT. However, this technique features an excessively 
high incidence of complications in the digestive tract.
Intensity-modulated radiation therapy (IMRT) is a novel ap-
proach to planning and delivery of radiation therapy. Nu-
merous investigators have demonstrated the benefits of 
IMRT for a variety of tumor sites in terms of normal tissue 
sparing (4,5) and delivery of radiation doses higher than 
conventional doses (6,7). IMRT can provide almost ideal 
dose distribution to the clinical target volume (CTV) while 
reducing the dose to normal tissue, thereby enhancing the 
effects and decreasing complications (8-10). Another ad-
vantage of IMRT is its ability to deliver differentiated doses 
to various structures during the same fraction dose irradia-
tion, thus allowing delivery of a higher dose to gross tu-
mor and lower dose to subclinical disease during the same 
treatment session.
The aim of the current study was to compare the thera-
peutic response and toxicity of IMRT and para-aortic field 
RT in patients with cervical cancer with PALN metastasis 
following conventional RT or surgery in order to develop 
an optimal treatment modality for this recurrent disease.
MeTHoDS
Patient population
Between November 1, 2004 and May 31, 2008, 60 patients 
were selected according to the following inclusion criteria: 
newly diagnosed PALN metastasis of cervical cancer, pre-
viously received conventional RT or surgery, a Karnofsky 
performance status score ≥70, and definitive IMRT or para-
aortic field RT received at Shandong Tumor Hospital and 
Institute (Jinan, China). Exclusion criterion was the pres-
ence of distant metastasis. Patients were serially assigned 
to one of two groups: the first patient in the series was as-
signed to group 1, the second patient to group 2, and so 
on. Patients in the group 1 received IMRT and patients in 
the group 2 received para-arotic field RT.
The study was approved by the hospital’s Institutional Re-
view Board and all patients gave their informed con-
sent for radiation therapy.
Chemotherapy
All patients were treated with 3 cycles of chemotherapy 
before RT. Patients with squamous cell carcinoma received 
either a combination of cisplatin (25 mg/m2, d1-3), vincris-
tine (1.25 mg/m2, d1, d8), and bleomycin (20 mg/m2, d1-3) 
(combination PVB), or a combination of cisplatin (25 mg/
m2, d1-3), etoposide (70 mg/m2, d1-5), and bleomycin (20 
mg/m2, d1-3) (combination PEB). Patients with adenocarci-
noma received a combination of cisplatin (25 mg/m2, d1-
3), etoposide (70 mg/m2, d1-5), and adriamycin (40 mg/
m2, d1) (combination PEA). Ureteral stent placement was 
done in 3 of 14 IMRT patients and 2 of 10 para-aortic field 
RT patients with hydronephrosis caused by tumor pressure 
before RT.
Radiotherapy
All patients underwent computed tomography (CT) scan-
ning in a supine position with their arms by their sides; the 
CT images were taken with a Panasonic CTX100 scanner 
(Beijing, China) at a 3-mm thickness throughout the entire 
abdomen and pelvic region.
IMRT plans to deliver the intended dose of 58-68 Gy with 
15 MV X-rays were developed for 28 patients. Para-aortic 
field RT was performed in the other 32 patients with an in-
tended dose of 45-50 Gy.
For IMRT, the RT was planned using the ADAC Pinnacle 3 
Treatment Planning System (Philips Radiation Oncology 
Systems, Milpitas, CA, USA) and treatment was delivered 
with 15-MV X-rays using a Varian 21EX. To reconstruct the 
GTV, we scanned the patient from the epigastrium to pel-
vic floor in order to locate the PALN metastasis. The GTV, 
CTV, planning target volume (PTV), the kidney, spinal cord, 
and small intestine were outlined on each image. The GTV 
was defined as any visible tumor on the image. The CTV 
was defined as the GTV plus a 2- to 5-cm margin above the 
highest extension of the tumor and a 4- to 5-cm margin 
below the lowest extension of the tumor with a 2-cm radi-
al margin. Uninvolved bony structure was kept outside the 
CTV. The PTV was defined as the CTV plus a 5-mm margin. 
The mean dose, dose range, and standard deviation (SD) of 
the PTV (for GTV boost and CTV) were calculated.
Dosimetric considerations
A 6- to 10-field, equally spaced, coplanar IMRT plan was 
generated for each patient using an identical starting set 
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of dose-volume constraints. Dose distribution was calcu-
lated by the 3D treatment planning system to include the 
target area with a 90% isodose curve. IMRT planning used 
dynamic multileaf collimators to shape the fields. In order 
to compare the exposure dose of organs at risk in patients 
who received IMRT, we designed a para-aortic 4-fields box 
plan for IMRT group using the ADAC system and planned 
to deliver the same prescription dose.
For para-aortic field RT planning we used the anteroposte-
rior and posteroanterior-field box plan. After the initial tu-
mor dose of 40 Gy was given in 20 fractions, the RT plan 
was changed into 2 anterior fields to achieve the intended 
prescription dose of 45-50 Gy, delivered as 2 Gy/fraction 
and 5 fractions/week.
Toxicity assessment
Acute toxicity levels were assessed weekly using complete 
blood cell counts and examinations for enteritis and skin 
reactions during the chemo-radiotherapy. Acute and late 
toxicities (occurring >90 days after the beginning of RT) 
were defined and graded according to Radiation Thera-
py Oncology Group criteria (11). Radiotherapy was inter-
rupted if there was uncontrolled diarrhea or other acute 
complications. In cases of grade 4 hematologic or non-he-
matologic toxicity, radiotherapy was stopped until toxicity 
resolved to at least grade 3.
Response assessment
The response of the metastatic lymph nodes was assessed 
by ultrasound, CT, or positron emission tomography-CT 
scanning after 1-3 months of treatment. A complete re-
sponse was defined as the complete disappearance of all 
measurable and assessable disease in ≥ 4 weeks. A 50% or 
more decrease in tumor size constituted a partial response.
Follow-up evaluation
Upon treatment completion, patients were evaluated ev-
ery 3 months for the first year, every 6 months during the 
following two years, and annually thereafter. At each vis-
it, a physical and pelvic examination, blood counts, clini-
cal chemistry, and chest X-rays were performed. Scans of 
the abdomen and pelvic region were conducted by ultra-
sound, CT scan, and/or positron emission tomography-CT.
Overall survival was calculated from the date of diagnosis. 
Surviving patients were censored on the date of the last 
follow-up. We confirmed the cause of death by mail, tele-
phone, or medical record review.
Statistical analysis
The overall survival curves were calculated using the Kaplan-
Meier method and compared using the log-rank test. Clini-
cal characteristics of patients, local control, survival rates, 
toxicities, and the dosimetric parameter were compared 
between the two groups using t-test and χ2 test. Statistical 
significance level was set at P < 0.05. All analyses were per-
formed using SPSS, version 13.0 (SPSS Inc., Chicago, IL, USA).
ReSuLTS
Patient characteristics are summarized in Table 1. There 
was no statistical difference in age, previously determined 
pathologic type, grade, and previous treatment modality 
between the two groups (P=0.282, P=0.068, and P=0.303, 
respectively). Patients who were lost to follow-up were ex-
cluded. In 3 of 32 (9.4%) patients from the para-aortic field 
RT group, therapy was stopped for a median of 11 days 
(range, 6 to 15 days) due to grade 3/4 acute enteritis. All of 
the patients in the study ultimately completed their radio-
therapy and received the full intended dose of RT.
outcome of follow-up
The median time of follow-up was 28 months (range, 3-45 
months). Up to May 2008, 4 of 28 (14%) patients from the 
TabLe 1. Clinicopathologic characteristics of intensity-modu-






field RT group 
(n = 32)
Age (years, median [range]) 48.5 (38-62) 50.0 (32-70)
Previous histopathologic grade*
Good or moderate 19 25
Poor  9  7
Previous histological type (No.)
Squamous cell carcinoma 20 25
Adencarcinoma  8  7
Previous treatment (No.)
Surgery and RT 17 11
RT 11 21
Cycles of chemotherapy  3  3
Intended RT dose (Gy) 60 45-50
Delivered RT dose (Gy, 
mean±standard deviation)
59.2±5.8 48.9±5.3
*based on Gauthier et al (12).
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IMRT group and 6 of 32 (19%) patients from the para-aor-
tic field RT group were lost, with follow-up rates of 86% 
and 81%, respectively. Of the 10 lost patients, 6 were out 
of contact and 4 did not appear at the reexamination. 
Their responses were not included in the data analysis. 
They also showed no significant differences from the pa-
tients who remained in the study in age (P=0.513), previ-
ously determined pathologic type and grade (P = 0.086), 
previous treatment modality (P = 0.144), or complications 
(P = 0.137).
Dosimetric considerations
The intended prescribed dose in the IMRT group was 58-68 
Gy (median, 63.5 Gy). The PTV received a total dose of 67.5 
Gy at 1.8-2.3 Gy/fraction, 5 fractions per week. Patients in 
the para-aortic field RT group received a total dose of 45-
50 Gy (median, 47.5 Gy) at 1.8-2.0 Gy/fraction. Table 2 sum-
marizes the dosimetric parameters of IMRT plans for 28 pa-
tients. Figures 1A and 1B show the isodose curves in cross 
section, sagittal section, and coronal section of one rep-
resentative patient treated by IMRT and para-aortic field 
RT, which indicate 90% isodose curve including the PTV. 
Figure 2 shows the dose-volume histogram of PTV and or-
gans at risk of one representative patient treated by IMRT 
and para-aortic field RT. Dose-volume histogram results for 
organs at risk analysis are described in Table 3. IMRT pro-
vided better critical organs sparing than para-aortic field 
RT based on mean dose and provided significantly better 
values for other parameters for the spinal cord, kidney, and 
small intestine. IMRT also allowed better dose reduction in 
organs at risk.
Tumor response and treatment outcome
As shown in Table 4, the rates for complete response and 
partial response were significantly higher in the IMRT 
group than in the para-aortic field RT group (complete re-
sponse: 57.1% vs 28.1%, P = 0.023; partial response: 32.1% 
vs 12.5%, P = 0.039).
The mean survival was 25 months (range, 3 to 27 months). 
The actuarial 2- and 3-year overall survival rates were sig-
nificantly higher in the IMRT group than in para-aortic field 
RT group (2-year: 58.8% vs 25.0%, P = 0.019; 3-year: 36.4% 
vs 15.6%, P = 0.016; Table 5). However, there was no sig-
Figure 1.
Isodose curves of a cross section, sagittal section, and coronary section of one representative patient for intensity-modulated radiation therapy (A) and 
one patient for para-aortic field radiotherapy (B).
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nificant difference in 1-year survival rate between the two 
groups (67.7% vs 51.3%, P =0.201). A plot of the survival 
curves is shown in Figure 3.
acute and chronic radiation toxicities
Acute major toxic effects included myelosuppression, der-
matitis, and enteritis. Grade 3/4 leukopenia occurred in 1 
of 28 (3.6%) patients in the IMRT group and 6 of 32 (19%) 
patients in para-aortic field RT group. Two (6.3%) patients in 
the para-aortic field RT group experienced grade 3 skin re-
actions. One (3.6%) patient in the IMRT group and 6 (19%) in 
the para-aortic field RT group experienced grade 3/4 acute 
enteritis. Grade 3/4 late radiation enterocolitis occurred in 6 
(19%) patients in the para-aortic field RT group after radio-
therapy. No patient experienced radiation myelitis.






IMRT para-aortic field RT IMRT para-aortic field RT
Conformity 0.680±0.067 0.300±0.054 0.910±0.067 0.350±0.057
V100% (%)  99.0±0.6  95.0±4.2  98.0±2.1  95.0±4.8
Dose (Gy) 59.00±0.48 49.00±1.13 58.60±0.87 48.60±0.74
*abbreviations: V100% – percent volume receiving the prescribed dose; conformity –the volume of the PTV/the volume receiving 
the prescribed dose.
Figure 2.
Dose-volume histogram (DVH) of a representative patient for intensity-
modulated radiation therapy (A) and para-aortic field radiotherapy (B): 
dash-double dot-dash – gross tumor volume; dash-dot-dash – planning 
target volume; dots – right kidney; em dashes – left kidney; solid line 
– spinal cord; en dashes – small intestine.
TabLe 3. Dose received by different organs at risk in inten-






field radiotherapy (Gy) t-test P
Spinal cord 26.1±9.8 46.3±30.8 3.327 0.001
Kidney 15.8±4.1 21.5±11.8 2.478 0.041
Small intestine 21.7±8.9 34.5±17.2 3.497 0.001
TabLe 4. Short-term treatment effects in intensity-modulated 
radiation therapy (IMRT) and para-aortic field radiotherapy 
(RT) patients*





field RT (n=32) χ2 P
Complete 16 (57.1)  9 (28.1)  5.173 0.023
Partial  9 (32.1)  4 (12.5)  3.395 0.039
Complete +partial 25(89.3) 13 (40.6) 15.227 0.001
*Criteria for complete response and partial response are defined in 
the Methods.
TabLe 5. overall survival rates in intensity-modulated radiation 
therapy (IMRT) and para-aortic field radiotherapy (RT) patients
 
overall
Percentage of patients who received 
(mean±standard deviation)
survival IMRT para-aortic field RT χ2 P
1-year 67.7±18.6 51.3±19.7 2.127 0.201
2-year 58.8±12.9 25.0±9.8 5.465 0.019
3-year 36.4±11.7 15.6±10.6 5.840 0.016
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Fifty-eight of 60 patients (96.7%) completed radiotherapy 
without interruption in a median time of 42 days (range, 
37-44). In 2 patients (3.3%), radiotherapy was interrupted 
for several days due to grade 3/4 skin or gastrointestinal 
tract toxicity; in these cases, radiotherapy was completed 
in 50 days.
The acute radiation toxicity of myelosuppression, dermati-
tis, and gastrointestinal tract was significantly lower in the 
IMRT group than in the para-aortic field RT group (3.6% 
vs 18.8%, P=0.005; 0 vs 6.3%, P=0.037; and 3.6% vs 18.8%, 
P=0.005; respectively). Moreover, the chronic radiation tox-
icity of radiation enterocolitis was also lower in the IMRT 
group (0 vs 18.8%, P=0.001).
DISCuSSIoN
Our study showed that IMRT provided better clinical out-
comes than para-aortic field radiotherapy in patients with 
PALN metastasis.
Although the use of higher radiation doses is associated 
with an improved likelihood of tumor eradication and en-
hanced pelvic control, it inevitably exposes organs at risk. 
In the last decade, many efforts, such as the rotation tech-
nique and the lateral-field radiation method, have been 
made to reduce the radiation dose and volume of organs 
at risk (13). However, protecting organs at risk remains a 
challenge. IMRT was found to be superior to conven-
tional techniques because it spares critical organs 
and provides adequate coverage of the target volumes 
(14,15). Paley et al (16) found that IMRT using 30-Gy ex-
ternal beam radiotherapy was superior to conventional 
therapy, especially when there was tumor regression and 
internal organ motion. Repeated IMRT planning can im-
prove sparing of the intestine and rectum in patients with 
substantial tumor regression. This technique was associ-
ated with an acceptable acute toxicity without significant 
treatment protraction (17).
In 5 cervical cancer patients with PALN involvement who 
received IMRT, Ahmed et al (18) demonstrated the feasi-
bility of increasing the dose delivered to grossly positive 
PALNs to 60 Gy with a 95.6% median GTV coverage. They 
found that PALN-IMRT caused less bone marrow exposure 
than AP/PA and 4-field box techniques: median exposure 
was 21.3%, 98%, and 49.7%, respectively. The doses re-
ceived by the kidney and small intestine were also signifi-
cantly lower. We found that, for the same PTV dose, IMRT 
made a better dose distribution and gave a significantly 
lower dose to organs at risk than para-aortic field RT.
In the present study, significant differences in digestive 
tract side effects and myelosuppression were found be-
tween the two groups, and the occurrence of proctitis and 
cystitis was lower in the IMRT group than in the para-aor-
tic field RT group. IMRT provided a better dose distribution 
than para-aortic field RT for treatment of PALN metastasis 
of cervical cancer after conventional RT or surgery and it 
led to lower acute and chronic radiation toxicities.
The effectiveness of IMRT in our study correlated with tar-
get volume, dose, and dose uniformity. If radical dose is 
not sufficient and GTV does not receive effective cover-
age, the metastases will not be cured. If the dose is not 
uniform, parts of GTV will receive lower doses, while if 
the dose is too high, it will couse serious irradiation in-
jury, even local necrosis. In the IMRT group in our study, 
the prescribed dose and the uniformity of target volume 
were adequate, with a median dose of 63.5 Gy delivered 
to the PTV and 90% of the isodose curve covering more 
than 99% of the CTV.
Our study showed encouraging short-term treatment ef-
fects and short-term survival benefits for patients with 
PALN metastasis of cervical cancer after conventional RT 
or surgery. The 2-year and 3-year survival rates were also 
significantly better in the IMRT group, as reported in oth-
er studies (19,20). However, the 1-year survival rates in the 
two groups were not significantly different.
Figure 3.
Kaplan-Meier survival curve showing overall survival for patients with 
recurrent cervical cancer: broken line – intensity-modulated radiation 
therapy group; dotted line – para-aortic field radiotherapy group.
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Ten out of 60 our patients (17%) were lost to follow-up. 
There was no significant difference in age, previously de-
termined pathologic type, grade, and previous treatment 
modality between patients lost to follow-up and those 
who completed the study. Previous studies reported an at-
trition range from 6.2% to 28.4% in different areas and dis-
ease stages (21-23).
Our results showed that IMRT provided better dose distri-
bution than para-aortic field RT and encouraging short-
term survival benefits in patients with PALN metastasis 
who had already been treated with conventional RT or sur-
gery. However, to observe the long-term survival rates and 
chronic toxicities, longer follow-up and greater number of 
patients are needed.
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